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This came naturally with the implementation of tests out of the com-
petition period of the athletes. For an athlete, it has been observed 
that the homeostasis of biosynthesis and metabolism of endogenous 
hormones was not disturbed by sports activity but of course will be 
influenced by the intake of similar substances. Actually, the passport 
has been defined as an individual and longitudinal observation of 
biomarkers. These markers need to belong to the biological cascade 
influenced by the application of forbidden hormones or, more gen-
erally, affected by biological manipulations that can improve the 
performance of the athlete.
Nowadays, only the hematologic passport of an athlete has been 
officially set up. This is a statistical representation of the longitu-
dinal follow-up of some blood biomarkers. This individual and 
longitudinal follow-up of blood parameters is of interest because 
the intraindividual variability is lower than the corresponding inter-
individual variability. Among the key points for the implementa-
tion of the ABP is its possibility to resist to the legal and scientific 
challenges. The ABP should be implemented in the most possible 
transparent way in the process and with the necessary independ-
ence between planning, interpretation, and result management of 
the passport.
To reach this transparency and efficiency, a new major actor has 
been introduced in the system to create a framework of independ-
ence: The athlete Passport Management Unit (APMU). The World 
Antidoping Agency (WADA) did implement new dedicated technical 
documents associated with the passport (hematologic module). This 
was done to allow the correct implementation of a profile that can 
resist any scientific or legal critics in following strictly some steps in 
the chain of production of the results and in the management of the 
interpretation of the passport.
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Summary: Several million people are exposed to dioxin and dioxin-
like compounds, primarily through food consumption. Skin lesions 
historically called ‘‘chloracne’’ are the most specific sign of abnor-
mal dioxin exposure and classically used as a key marker in humans. 
We followed up for 5 years a man who had been exposed to the 
most toxic dioxin, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 
at a single oral dose of 5 million-fold more than the accepted 
daily exposure in the general population. We adopted a molecu-
lar medicine approach, aimed at identifying appropriate therapy. 
Skin lesions, which progressively covered up to 40% of the body 
surface, were found to be hamartomas, which developed parallel 
to a complete and sustained involution of sebaceous glands, with 
concurrent transcriptomic alterations pointing to the inhibition of 
lipid metabolism and the involvement of bone morphogenetic pro-
teins signaling. Hamartomas created a new compartment that con-
centrated TCDD up to 10-fold compared with serum and strongly 
expressed the TCDD-metabolizing enzyme cytochrome P-450 1A1, 
thus representing a potentially significant source of enzymatic activ-
ity, which may add to the xenobiotic metabolism potential of the 
classical organs such as the liver. This historical case provides a 
unique set of data on the human tissue response to dioxin for the 
identification of new markers of exposure in human populations. 
The herein discovered adaptive cutaneous response to TCDD also 
points to the potential role of the skin in the metabolism of food 
xenobiotics.
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Summary: In New Zealand, there has been discussion around the 
value of evidence-based medicine in primary care and the case for 
complementary practice-based evidence that could feed back into 
the evidence from clinical trials on the generality and applicability 
of the interventions in the “real-life” context.1 It is clear that data-
bases of adverse drug reaction (ADR) reports are, in fact, a source 
of practice-based evidence.
In 1965, New Zealand became 1 of the first countries to collect 
and assess reports submitted by health professionals of suspected 
ADRs in individual patients. This collection is the database of the 
Centre for Adverse Reactions Monitoring (CARM) based in the 
New Zealand Pharmacovigilance Centre. Distinctive features of the 
New Zealand database are the high proportion of well-documented 
reports, and, frequently, the highest reporting rate/population in 
international comparisons. New Zealand was also a founding mem-
ber of the WHO International Drug Monitoring Programme.
Databases of ADRs were established to generate hypotheses to be 
tested about previously unrecognized adverse reactions and interac-
tions. Occasionally, they contain sufficient evidence in themselves. 
They can also identify prescribing practices that might increase the 
potential for ADRs to occur. They can feed back into guidelines the 
consequences of their use or nonuse and identify unexpected prob-
lems that arise with issues such as pathways to accessing funded med-
icines. Well-documented ADR reports can also highlight risk factors, 
thus providing a valuable contribution to risk/benefit assessments in 
individual patients. Examples from the New Zealand database and 
from international collaboration will be discussed that support the 
use of ADR reports as practice-based evidence in a nonhierarchical 
system in which case reports and case series, observational studies, 
and randomized clinical trials contribute in a flexible relationship 
depending on the issue under investigation.
One of the major challenges in optimizing the contribution of 
ADR databases to clinical practice is the provision of feedback that 
aids prescribing and also stimulates the quality as well as quantity 
of reporting.
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Summary: Risk perception associated with medicines information 
affects drug therapy and drug adherence. One problem is inconsist-
encies between sources providing medicines information, which give 
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rise to confusion about drug safety. Risk perception among health 
care professionals and the public differ in many aspects, and so does 
need and quality of drug information. In this presentation, experi-
ence from regional medicines information and pharmacovigilance 
centers in Norway (RELIS) serving health care professionals are 
described. In particular, through a public service started in 2011, 
“SafeMommyMedicine,” RELIS inform pregnant and breastfeeding 
women about risk associated with use of medicines. In parallel with 
this, we focus on research projects in which our service toward both 
target groups is evaluated.
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Summary: By 2014 in the United Kingdom, a system of “value-
based pricing” (VBP) will replace the current Pharmaceutical Price 
Regulation Scheme (PPRS), which is a voluntary agreement between 
the UK Department of Health (DH) and the pharmaceutical indus-
try whereby companies negotiate profit rates from drug sales to the 
National Health Service (NHS) every 5 years. The concept of VBP is 
that prices of individual pharmaceutical products should reflect their 
“clinical and therapeutic value to patients and the broader NHS.” 
This talk describes a potential framework for VBP in the type of 
devolved NHS envisioned in recent UK government reforms. It also 
considers some of the critical features of VBP arrangements that 
need to be appropriately specified if the potential benefits are to be 
realized. The introduction of VBP provides an opportunity to found 
pharmaceutical pricing and access to new health technologies on 
sound principles, reflective of social values and the reality of a budget-
constrained NHS. This requires clarity on key issues of principle and 
social value, as well as critical details of how it will be implemented 
and operate. Any assessment of value must be founded on the type 
of transparent scientific assessment of the costs and benefits offered 
by a technology that is already embodied in the National Institute 
for Health and Care Excellence (NICE) appraisal process. It is also 
important that the assessment of the health expected to be forgone 
elsewhere in the NHS due to additional costs displacing other NHS 
activities (ie, the cost-effectiveness threshold) is evidence based. In 
addition, transparent rules of how prices might be negotiated based 
on such assessments are required.
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The Council for International Organizations of Medical Sciences 
(CIOMS) was established by WHO and UNESCO in 1949. One of its 
major objectives has been to contribute to harmonized approaches to 
international systems and terminology used for the safety surveillance 
of medicinal products and vaccines by the publication of consensus 
reports that discuss and recommend general principles. It has hence 
proved crucial to involve experts from drug regulatory authorities, 
research-based biopharmaceutical companies, WHO, academia, and 
public health bodies.
Covered areas of the life cycle of medicinal products have been 
international reporting of adverse drug reactions (the CIOMS I 
reporting form), Adverse Drug Reaction terminology, Standardized 
MedDRA (R) Queries (SMQs), management of safety data from clini-
cal trials, periodic drug safety updates in the pre- and postapproval 
phases, core clinical safety information on drugs under development, 
proposals for harmonized safety information in data sheets or pack-
age inserts, approaches for assessing benefit/risk, pharmacogenetics, 
and pharmacovigilance in resource-limited countries. The 2 most 
recent CIOMS publications cover safety signal detection and man-
agement1 and definition and application of terms for vaccine phar-
macovigilance.2
The ongoing CIOMS Working Group on Practical Considerations 
for Development and Application of a Toolkit for Medicinal Product 
Risk Management has undertaken the challenging task of defining 
fundamental principles that should underlie efforts to minimize or 
mitigate the risks associated with medicines. Risk management also 
involves interaction with health care systems and to increase the 
likelihood of relevance, acceptability, and feasibility of the risk mini-
mization strategy a stakeholder subgroup within Working Group IX 
considered the input from patients, physicians, other HCPs, health 
insurance carriers, and reimbursement bodies.
Meta-analyses and systematic reviews have been increasingly 
used in the scientific evaluation of efficacy and safety for benefit/risk 
assessments, as well as the pricing and reimbursement of biopharma-
ceutical products in clinical practice. CIOMS currently has an ongo-
ing Working Group aimed at developing a consensus on scientific and 
methodological criteria that represent good practices when applied to 
meta-analyses of clinical data within the regulatory process.
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Summary: Lipid-lowering therapy with statins has become the 
cornerstone in the prevention of (recurrent) cardiovascular disease 
(CVD). Statins reduce low-density lipoprotein (LDL)-cholesterol by 
30% to 60% and CVD risk by 25% to 30%. Recent European guide-
lines recommend a LDL-cholesterol goal of < 2.5 mmol/L in patients 
with high CVD risk and even lower in patients with very high risk, 
< 1.8 mmol/L or ≥ 50% reduction in LDL-cholesterol. In patients 
with severe hyperlipidemia as well as in patients who are intolerant of 
statins, these goals cannot be reached. Hence, there is a need for novel 
therapeutic modalities that lower atherogenic lipoproteins in addition 
to statins or alternatively increase protective lipoproteins (HDL).
Several promising new therapeutic approaches have been devel-
oped recently. First, antisense oligonucleotides (ASOs) have been 
proven to be effective in lowering apolipoproteins. ASOs are short 
single strands of DNA that are complimentary in sequence to a seg-
ment of mRNA of specific proteins; after binding to mRNA, trans-
lation and the production of the protein are prevented. The first 
antisense inhibitor of apoB, the structural protein of the atherogenic 
